Roflumilast Topical (Zoryve)
Jump to navigation
Jump to search
Indications
- treatment of ezcema (FDA-approved)
- treatment of plaque psoriasis
- treatment of seborrheic dermatitis
Dosage
- 0.15% cream for treatment of eczema
- 0.3% cream for treatment of plaque psoriasis
- 0.3% foam for treatment of seborrheic dermatitis
- 0.3% foam once daily for scalp & body psoriasis[2]
Adverse effects
Mechanism of action
- see roflumilast
More general terms
References
- ↑ Brunk D Roflumilast Cream 0.15% Approved for Eczema in Patients Aged 6 or Older. Medscape, July 10, 2024 https://www.medscape.com/viewarticle/roflumilast-cream-approved-eczema-patients-2024a1000cpx
- ↑ Jump up to: 2.0 2.1 Gooderham MJ, Alonso-Llamazares J, Bagel J et al Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2025 May 7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/40332898 https://jamanetwork.com/journals/jamadermatology/fullarticle/2833460